Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tomivosertib · EFT-508

Small molecule · Inhibitor of MNK1 (MKNK1) and MNK2 (MKNK2) · developed by Effector Therapeutics

Phase 2 Most advanced trial (none active)
1 Registered trials

What is Tomivosertib?

Tomivosertib is an orally bioavailable inhibitor of MNK1 and MNK2 serine/threonine kinases. It prevents MNK-mediated phosphorylation of eIF4E and other regulatory proteins, inhibiting translation of mRNAs involved in tumor proliferation, angiogenesis, and survival. It is studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
EFT-508
Drug type
Small molecule
Targets
MNK1 (MKNK1), MNK2 (MKNK2), eIF4E (secondary target)
Mechanism
Inhibitor of MNK1 (MKNK1) and MNK2 (MKNK2)
Pathways
MAPK signaling, translation initiation, tumor cell proliferation, angiogenesis, immune signaling
Therapy area
Oncology
Developer
Effector Therapeutics
In trials of
MEDP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
U2H19X4WBV

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04622007 Phase 2 Non-small Cell Lung Cancer Unknown MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-small Cell Lung Cancer

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.